HealthTree Logo
search more_vert
person Sign In / Create Account

The prognosis for cutaneous T-cell lymphoma (CTCL) varies greatly depending on several factors, including the stage of the disease at diagnosis, the patient's overall health, and the specific subtype of CTCL. It's important to note that while statistics can provide a general idea, they cannot predict the exact outcome for an individual patient.

What Do Statistics Say About the Life Expectancy for Someone with Cutaneous T-Cell Lymphoma?

Statistics for CTCL are difficult to come by due to the rarity of this disease, and really depends on the subtype of CTCL a person has.

Early-stage mycosis fungoides has been associated with a long survival. A recent study from 2019 looking at stage IB–IVB mycosis fungoides (MF) and Sezary syndrome found that 10-20% of stage IB patients don't survive 5 years while patients with advanced-stage mycosis fungoides and Sezary syndrome have a 5-year survival of about 20-60%. 

Another study found that for those with mycosis fungoides, the predicted 10-year overall survival rate was 90.3% for early-stage disease compared to 53.2% for advanced-stage disease. 

This 2018 study reported median overall survival for mycosis fungoides patients with stage IIB disease was 68 months compared to 48 months for those with stage IVA disease and 33 months for those with stage IVB disease. In this study, patients with the following characteristics had higher rates of disease progression: plaque lesions involving than 10% of the body surface, high lactate dehydrogenase, high beta-2-microglobulin and stage IB disease.

What Factors Affect Prognosis for Cutaneous T-Cell Lymphoma?

  • Stage of the disease: The stage of CTCL at the time of diagnosis is one of the most important factors. Early-stage disease (stage I or II) generally has a better prognosis than advanced-stage disease (stage III or IV).
  • Age and overall health: Younger patients and those in good overall health typically have a better prognosis.
  • Type of CTCL: There are several subtypes of CTCL, some of which have a better prognosis than others. For example, patients with mycosis fungoides generally have a better prognosis than those with Sézary syndrome.
  • Response to treatment: Patients who respond well to initial treatment often have a better prognosis.

It's important to note that survival statistics are general trends and a patient's individual prognosis can vary greatly. Each patient's case is unique and should be discussed with their healthcare provider. Having an CTCL specialist on your team provides you with the best way of truly understanding your prognosis. Visit HealthTree's CTCL Specialist Directory to find an ALL expert near you. You can also join HealthTree's social media platform, HealthTree Connect to meet other CTCL patients and learn what they've done personally to live longer with ALL. 

Want to Learn More About Cutaneous T-Cell Lymphoma?

Keep reading HealthTree for Cutaneous T-Cell Lymphoma's 101 pages!

Get the latest thought leadership on Cutaneous T-Cell Lymphoma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Cutaneous T-Cell Lymphoma Newsletter" for Cutaneous T-Cell Lymphoma news, life with Cutaneous T-Cell Lymphoma stories, Cutaneous T-Cell Lymphoma clinical trials, Cutaneous T-Cell Lymphoma 101 articles and events with Cutaneous T-Cell Lymphoma experts.